Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomerica (BMRA) EPS (Weighted Average and Diluted) (2016 - 2025)

Biomerica's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at -$0.45 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 650.0% year-over-year to -$0.45; the TTM value through Nov 2025 reached -$1.92, up 43.03%, while the annual FY2025 figure was -$2.16, 23.94% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.45 at Biomerica, down from $0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.0 in Q3 2025 and bottomed at -$2.57 in Q2 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.12 (2021), against an average of -$0.33.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 2470.0% in 2024 before it soared 100.12% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.09 in 2021, then tumbled by 33.33% to -$0.12 in 2022, then increased by 25.0% to -$0.09 in 2023, then soared by 33.33% to -$0.06 in 2024, then plummeted by 650.0% to -$0.45 in 2025.
  • Per Business Quant, the three most recent readings for BMRA's EPS (Weighted Average and Diluted) are -$0.45 (Q4 2025), $0.0 (Q3 2025), and -$1.41 (Q2 2025).